Results 191 to 200 of about 3,367,821 (256)

Myeloproliferative Disorders

Hematology/Oncology Clinics of North America, 2014
The emergency providers generally encounters myeloproliferative disorders (MPNs) in 1 of 2 ways: as striking laboratory abnormalities of seeming unknown consequence, or in previously diagnosed patients presenting with complications. The course of patients with MPNs is highly variable, but major complications can arise.
Brian, Meier, John H, Burton
semanticscholar   +5 more sources

The Myeloproliferative Disorders

New England Journal of Medicine, 2006
The discovery of an identical mutation (V617F) of the JAK2 gene in patients with polycythemia vera, essential thrombocythemia, and myelofibrosis — the principal Philadelphia chromosome–negative myeloproliferative disorders — has greatly advanced our understanding of these conditions.
Peter J, Campbell, Anthony R, Green
openaire   +3 more sources

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.

European journal of medicinal chemistry, 2020
The Janus kinases or JAKs are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of autoimmune diseases and myeloproliferative disorders.
Pengfei Xu   +9 more
semanticscholar   +1 more source

Myeloproliferative disorders

Medicine, 2004
Myeloproliferative disorders are caused by abnormalities of hematopoietic stem cells leading to uncontrolled proliferation of one or more cell lines in the blood. Besides sharing common clinical and hematologic features they are characterized by clonal hematopoiesis and genetic instability, resulting in a disease-specific rate of transformation into ...
D, Binder, J, Fehr
  +6 more sources

Myeloproliferative disorders

Best Practice & Research Clinical Haematology, 2001
The myeloproliferative disorders (MPDs) are a group of pre-leukaemic disorders characterized by proliferation of one or more lineages of the myelo-erythroid series. Unlike the Philadelphia chromosome in chronic myeloid leukaemia, there is no pathognomonic chromosomal abnormality associated with the MPDs.
Bench, Anthony J.   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy